Aileron Therapeutics is a clinical stage chemoprotection oncology company. Co.'s product candidate, ALRN-6924, is a MDM2/MDMX dual inhibitor that utilizes its proprietary peptide drug technology. When used as a chemoprotective agent, ALRN-6924 is designed to activate p53, which in turn upregulates p21, an inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. The ALRN YTD return is shown above.
The YTD Return on the ALRN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ALRN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ALRN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|